Studies have shown large variations in the diagnostic intervals (the time from the first presentation of symptoms in primary care until diagnosis) for colorectal cancer (CRC) patients, with some patients experiencing intervals of months ([@bib4]; [@bib16]; [@bib11]; [@bib31]). Although early diagnosis of cancer is generally deemed desirable, some clinicians and researchers are sceptic about the benefits of expediting diagnosis for CRC patients ([@bib14]; [@bib3]; [@bib28]). The reasoning is that diagnostic intervals, measured in weeks to months, may be negligible by comparison with the time required for the development of the tumour, measured in years ([@bib23]; [@bib22]; [@bib2]; [@bib15]; [@bib31]).

Studies have shown an important, but modest, reduction in CRC mortality by screening, indicating that time to diagnosis may matter ([@bib12]; [@bib1]). However, the majority of CRC patients are diagnosed after presenting with symptoms, and no randomised trials have examined the benefits of expediting diagnosis in symptomatic patients ([@bib18]). Most of the published literature report data, inevitably, from observational studies. A recent review indicated a lack of association between the diagnostic interval and mortality in CRC patients, but the authors emphasised that future studies should focus on adjusting for confounding factors, as many of the included studies had counterintuitive results, showing that patients with short diagnostic intervals had higher mortality than patients with long diagnostic intervals ([@bib26]). Such findings are usually referred to as the 'waiting time paradox\' and have also been reported for other types of cancer ([@bib19]).

The aim of this study was to analyse the association between the diagnostic interval and mortality after diagnosis of CRC, while taking account of the interpretation of symptoms by the general practitioner (GP) and controlling for confounding factors at first presentation.

Materials and methods
=====================

We conducted a cohort study with overall 3-year mortality as the primary outcome and the diagnostic interval as the exposure variable.

Setting
-------

The cohort resided in the former Aarhus County, Denmark, which has 640 000 inhabitants and ∼400 new CRC cases per year ([@bib20]). Denmark\'s publicly funded health-care system provides free access to general practice and hospital care. More than 98% of Danish citizens are registered with a GP whom they have to consult for medical advice. The GP acts as a gatekeeper to the rest of the health-care system, carrying out initial diagnostic investigations and referring patients to hospitals or outpatient clinics when necessary. Danish GPs are legally bound to keep detailed medical records of their patients ([@bib6]).

Study population
----------------

Our study included all newly diagnosed CRC patients over the age of 17 during 1 year (1 September 2004 to 31 August 2005). Subsequently, the study population was restricted to the 89.8% of patients who had attended general practice before the cancer diagnosis (see flowchart, [Figure 1](#fig1){ref-type="fig"}).

Identification of patients and GPs
----------------------------------

Register data for this study were linked by means of the civil registry number, a unique personal identifier assigned to all Danish citizens at birth. Patients were identified from the County Hospital Discharge Registry, a population-based medical database that records dates of all inpatient and outpatient visits and discharge diagnoses classified according to the International Classification of Diseases (ICD-10). We defined incident CRC patients as patients registered with a first-time discharge diagnosis of colon cancer (C18 and C19) or rectal cancer (C20) during the study period; and with no previous diagnosis of colon cancer, rectal cancer, or malignant neoplasm of ill-defined, secondary, and unspecified sites (C76-80).

In 2009, we verified all diagnoses by comparing the data with the Danish Cancer Registry, which records all incident cancer cases in Denmark and holds key information from the Danish National Pathology Registry. To identify the patients\' GPs, the data were linked to the County Health Service Registry ([@bib29]).

Data collection
---------------

A questionnaire was sent to each patient\'s GP. In practices with more than one GP, we asked the GP most familiar with the patient to complete the questionnaire. The GPs received compensation for their participation (DKK 240 equivalent to EUR 32). Nonresponders received a reminder after 3 weeks. The GPs were asked to confirm the diagnosis and provide a detailed description of the patient\'s diagnostic pathway on the basis of the electronic medical record and discharge letters from hospitals and specialists (e.g., dates of reported symptoms, encounters, tests, referrals, and involvement of other providers). GP involvement was defined on the basis of the question: 'Were you/your general practice involved in diagnosing the cancer?\' (yes/no). The questionnaire also requested information about the symptoms presented by the patients at the first consultation and about the GP\'s interpretation of those symptoms, that is, as either alarm symptoms suggestive of cancer, symptoms suggestive of any serious illness, or vague symptoms not directly suggestive of cancer or other serious illness. This allowed us to distinguish between patients presenting with either 'alarm or any serious symptoms\' or 'vague symptoms\'. The GP\'s symptom interpretation was subjective, that is, not based on a prespecified list of alarm symptoms. The data collection has been described in further detail elsewhere ([@bib10]; [@bib11]).

Data on covariates
------------------

We obtained information on age and sex from the civil registry number. The patients\' complete hospital discharge history, 10 years before the date of first presentation of symptoms to the GP, was used to compute a Charlson Comorbidity Index score ([@bib5]). We grouped levels of comorbidity into 'no comorbidity\' (patients with no recorded disease), 'patients with moderate comorbidity\' (index score of 1 and 2), and 'patients with high comorbidity\' (index score of ⩾3). To describe data in further detail, we obtained information from the Danish National Registry of Patients on emergency admission (yes/no) and from the Danish Cancer Registry on previous cancers in other sites (yes/no) and tumour staging classified according to the TNM staging system. We re-grouped the staging information using the following principle: stage I (T1-2/N0/M0), II (T3-4/ N0/M0), III (T1-4/N1-2/M0), IV (T1-4/N0-2/M1), and unknown.

Defining time and mortality
---------------------------

From the Danish Civil Registration System we retrieved information on migration and death. The study outcome was death. All patients were followed for at least 3 years after diagnosis. When comparing mortality in patients with participating and nonparticipating GPs, the date of the first-time discharge diagnosis of cancer in the County Hospital Discharge Registry was taken to be the date of diagnosis.

Statistical analyses
--------------------

We stratified analyses according to the interpretation of symptoms by the GP (alarm or any serious symptoms *vs* vague symptoms), as we expected the diagnostic pathways to be very different for these two groups of patients. We initially stratified data into colon and rectal cancer, as suggested by [@bib26]), but, as the effect was constant across tumour site, data were pooled to enhance statistical precision.

The diagnostic interval was grouped into 'short\' 0--4 weeks (0--28 days), 'medium\' 5--11 weeks (29--77 days), and 'long\' ⩾12 weeks (78+ days) roughly based on the 25th and 75th percentiles and in accordance with the waiting time guarantee of 4 weeks endorsed by the Danish Government ([@bib21]).

To estimate the odds ratio (OR) of experiencing long *vs* short and medium diagnostic intervals for patients presenting with vague symptoms *vs* patients presenting with alarm or any serious symptoms, we used logistic regression and adjusted for tumour site (colon/rectal), Charlson Comorbidity Index (0/1--2/⩾3), age (18--59/60--74/⩾75), and sex.

Patients who died on the date of diagnosis were included in the analyses. The survival function up till 3 years after diagnosis was plotted for each of the three groups of diagnostic interval. We used logistic regression to estimate 1-year and 3-year mortality OR as a function of the diagnostic interval adjusted for tumour site, Charlson Comorbidity Index, age, and sex. We modelled the data in two ways: first, we calculated the adjusted OR for short or long *vs* medium diagnostic intervals.

Second, we treated the diagnostic interval as a continuous variable using restricted cubic splines in order to make efficient use of within-category information ([@bib9]). We chose an *a priori* reference point of 4 weeks (28 days) and used four knots.

To address the possibility that emergency admission was a confounder and not an intermediate step in the diagnostic pathway, we additionally adjusted for emergency admission and repeated the analyses after excluding patients with emergency admissions.

We calculated 95% confidence intervals (95% CIs) for all estimates and tested each model against a model with no diagnostic interval term using the Wald test. A two-sided *P*-value of ⩽0.05 was defined as statistically significant.

Results
=======

We identified 363 incident CRC patients over the age of 17 years. In 58 (16.0%) of the cases, the GPs did not participate or complete the questionnaire ([Figure 1](#fig1){ref-type="fig"}). We found no discrepancies between patients with participating GPs and nonparticipating GPs with respect to 1-year and 3-year mortality after discharge, age, gender, comorbidity, tumour stage, previous cancer, or emergency admission ([Table 1](#tbl1){ref-type="table"}).

Out of the 305 incident CRC patients with participating GPs, we excluded 37 (12.9%) for whom the GP was not involved in diagnosing the cancer ([Figure 1](#fig1){ref-type="fig"}). Compared with the 268 patients with GP involvement, patients with uninvolved GPs were more likely to be admitted to hospital as an emergency ([Table 1](#tbl1){ref-type="table"}).

The odds of experiencing long *vs* short diagnostic intervals (adjusted for comorbidity, age, and sex) were 3.99-fold (95% CI: 2.10, 7.56) higher for the 67 patients presenting with vague symptoms than for the 201 patients presenting with alarm symptoms or any serious symptoms. Patients presenting with vague symptoms had lower levels of comorbidity and were less likely to present with blood in stools than patients with clear symptoms ([Table 2](#tbl2){ref-type="table"}).

Diagnostic interval and mortality
---------------------------------

Overall, 63 (23.5%) CRC patients died within 1 year, and 113 (42.2%) within 3 years of diagnosis ([Figure 2](#fig2){ref-type="fig"}).

In patients presenting with alarm symptoms or any serious symptoms, the adjusted 3-year mortality OR was 2.56 (95% CI: 1.29, 5.05) for short and 2.04 (95% CI: 0.87, 4.77) for long compared with medium diagnostic intervals ([Table 3](#tbl3){ref-type="table"}). The cubic splines regression analysis ([Figure 3](#fig3){ref-type="fig"}) revealed that the risk of dying within 3 years began to increase after 5 weeks of diagnostic interval (*P*=0.002).

In patients presenting with vague symptoms, the adjusted 3-year mortality OR was 0.71 (95% CI: 0.32, 2.91) for long compared with medium diagnostic intervals. As only 10 patients had short diagnostic intervals, comparison with this group was not justified. The cubic splines regression analysis ([Figure 3](#fig3){ref-type="fig"}) revealed a reverse effect with increasing risk of dying from day 1 and up to ∼12 weeks, but the association was not statistically significant (*P*=0.205).

When analysing 1-year mortality ([Table 3](#tbl3){ref-type="table"}), adjusting for emergency admission or excluding patients with emergency admissions, we found similar trends and no major changes in estimates (data not shown).

Discussion
==========

In this population-based cohort study of 268 incident CRC patients attending primary care before diagnosis, mortality decreased with diagnostic intervals up to ∼5 weeks, after which mortality increased. The counterintuitive finding of short waiting time being associated with high mortality only applied to patients presenting with alarm symptoms or any serious symptoms. In the quarter of patients presenting with vague symptoms, the association was reverse although not statistically significant.

Strengths of the study
----------------------

The strengths of the study lie in the population-based design made possible by a uniformly organised health-care system and validation using histological confirmation of diagnoses and complete follow-up, all of which reduced selection and information bias. The high response rate among GPs (84.0%) also reduced the potential for selection bias. By excluding patients in whose diagnosis the GPs had not been involved, we ensured a more accurate measure of the exposure (the diagnostic interval) and a more homogeneous group with respect to confounders; and thus obtained better internal validity. Furthermore, the analyses were strengthened by allowing between-site variability in delay and mortality and a nonmonotonic effect ([@bib17]); and by addressing confounding by indication as discussed further below.

Limitations of the study
------------------------

The limitations relating to the study design include possible selection bias, information bias, and residual confounding.

First of all, 16.0% of the study base could not be included in the final analyses because of nonparticipation of GPs. As seen on [Table 1](#tbl1){ref-type="table"}, patients with nonparticipating GPs shared many of the same clinical features as patients with uninvolved GPs, including equal mortality rates. Thus, the GPs may not have been involved in diagnosing cancer for a substantial part of these patients (if patients, e.g., presented with emergency conditions and bypassed their GP). Nevertheless, we cannot reject that some GPs may have chosen not to participate, because they retrospectively believed they had caused undue delays in diagnosing cancer. Given the observed convex and concave trends, it is difficult to predict the direction of the bias due to selection.

Second, given the retrospectively collected data and the comprehensive knowledge of GPs of their patients, we cannot rule out differential misclassification regarding the length of the diagnostic interval. Such misclassification would occur if, for example, the GPs tended to understate the lengths of the diagnostic intervals for patients who died shortly after diagnosis or were diagnosed with advanced-stage cancers. If this were to be the case, it would explain some of the excess mortality among patients with short diagnostic intervals. To reduce information bias, GPs were encouraged to consult their electronic medical records.

The consistent findings of higher mortality for short diagnostic intervals among patients presenting with alarm symptom or any serious symptoms -- even after adjustment and exclusion of patients with emergency admissions -- could also be an indication of residual confounding. Unknown confounding such as tumour aggressiveness may have reversed the association, as patients with rapidly growing tumours may exhibit more symptoms that may raise appraisal and lead to shorter diagnostic intervals, but ever worse outcomes. Although we were unable to account for the speed of tumour growth and/or aggressive malignancies, we partly dealt with confounding by appraisal by stratifying data according to the symptom interpretation of the GP. This will be discussed further below.

Finally, although it was an important tool in limiting the risk of confounding, the stratification procedure and restriction also reduced the power of the study. A larger study is needed to assess the effect in patients presenting with vague symptoms.

Comparison with findings from other studies
===========================================

Most previous studies have examined the influence of total delay (time from first symptom to treatment), total diagnostic delay (time from first symptom to diagnosis), or provider delay (time from first presentation of symptoms to treatment). Common for all these studies is the mixing of patient, diagnostic, and/or treatment delays. From a methodological point of view, it is particularly tricky that both the prognostic factors and the premises for sorting patients are likely to change during the pathway to treatment. The best example is tumour stage, which is an important prognostic factor at the time of diagnosis and surely a confounder of the association between treatment delay and mortality. But, it does not qualify as a confounder of the association between diagnostic delay and mortality because it succeeds presentation. If we control for this factor in studies of diagnostic delay, we create confounding.

Over the past three decades, the association between time to diagnosis and mortality has been the subject of at least 14 studies based on data from symptomatic colon and/or rectal cancer patients ([@bib14]; [@bib23]; [@bib22]; [@bib13]; [@bib8]; [@bib3]; [@bib25]; [@bib2]; [@bib24]; [@bib17]; [@bib7]; [@bib28]; [@bib30]; [@bib31]). The studies report either no statistically significant association or the waiting time paradox. The present study is pioneering in the sense that it challenges the premises of former models. The finding of a U-shaped association between the length of the diagnostic interval and mortality after diagnosis of cancer provides evidence that previous studies may not have represented reality very well; either because they did not allow for a continuous, nonmonotonic effect ([@bib13]; [@bib25]; [@bib28]) or because they introduced bias by adjusting for intermediate variables such as tumour stage ([@bib23]; [@bib7]; [@bib30]; [@bib31]). This is the first study to address these issues while at the same time controlling for confounding factors at first presentation of symptoms in primary care.

Apart from contesting previous models, we believe that the results may also challenge former reasoning. It has often been speculated that the consistent findings of higher mortality for short delays was caused by hidden confounders like the tumour\'s speed of growth and/or its ability to spread ([@bib22]; [@bib2]; [@bib28]). According to this theory, aggressive tumours are associated with shorter delays because they are easier to appraise ([@bib19]). However, for this theory to hold true, we would expect patients presenting with vague symptoms to have an overall better survival than patients presenting with alarm or any serious symptoms and to see similar trends for the two groups. Apparently, this is not the case.

Underlying mechanisms and clinical implications
-----------------------------------------------

We believe that the contradictory findings of the waiting time paradox mainly reflects confounding by indication, that is, a bias stemming from the inherent difference in prognosis of patients given different medical priority ([@bib27]). This mechanism occurs if GPs, and subsequently diagnostic imaging centres and endoscopic centres, as expected, give priority to seriously ill patients who may have higher inherent mortality (the 'sick-quick\' group), whereas being more reluctant to expedite patients with less obvious symptoms of cancer (the 'low risk--slow diagnosis\' group). This may even be supported by the fast-track guidelines. The association of short diagnostic intervals and high mortality in patients with alarm or serious symptoms and corresponding long diagnostic intervals and low mortality in patients with vague symptoms strongly supports the presence of this mechanism.

To conclude, most of the potential biases (from selection, misclassification, confounding, and/or random error) will either have influenced the results towards the null hypothesis or reversed the association. Based on this observational study, we can only speculate on the exact cause of the increased mortality with longer diagnostic intervals. A biological explanation could be that the exponential growth of the tumours predicates early diagnosis as a crucial factor even for patients presenting with vague symptoms. However, it should always be kept in mind that observational studies do not test the hypothesis that expediting diagnosis provides a mortality benefit. The diagnostic interval is a highly complex variable reflecting tumour biology, patient behaviour, the clinical pathway, and the functioning of the health-care system. This study\'s significance is that it provides some evidence against the hypothesis that the diagnostic interval has no effect on mortality and thus speaks against the tendency to downplay the importance of the diagnostic interval.

Conclusion
==========

On the basis of detailed primary-care data, this study shows the waiting time paradox together with an increasing mortality with longer diagnostic intervals in CRC patients presenting with alarm or serious symptoms.
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![Flowchart showing identification of incident colorectal cancer (CRC) patients in Aarhus County, Denmark, 2004--2005, for whom general practice was involved in diagnosing the cancer. The last criterion could not be determined for patients with nonparticipating GPs.](bjc201160f1){#fig1}

![Estimated survival according to the length of diagnostic nterval analysed for colorectal cancer patients presenting with (**A**) alarm symptoms of cancer or symptoms related to any serious illness and (**B**) vague or ill-defined symptoms not directly related to cancer or any other serious illness. The solid curves indicate 0--4 weeks; dashed curves indicate 5--11 weeks; and dotted curves indicate ⩾12 weeks from first presentation of symptoms in primary care to diagnosis (the diagnostic interval).](bjc201160f2){#fig2}

![Estimated 3-year mortality odds ratios (ORs) as a function of the diagnostic interval (time from first presentation of symptoms in primary care until diagnosis) analysed for colorectal cancer patients presenting with (**A**) alarm symptoms of cancer or symptoms related to any serious illness and (**B**) vague or ill-defined symptoms not directly related to cancer or any other serious illness. We adjusted for tumour site (colon/rectal), Charlson Comorbidity Index (0/1--2/⩾3), age (18--59/60--74/⩾75), and sex. The solid curves indicate adjusted estimates with point-wise 95% confidence limits in grey. The dashed curves indicate crude estimates. The grey spikes show the distribution of the diagnostic intervals on a squared scale. The grey horizontal lines indicate the chosen reference point of 4 weeks (28 days).](bjc201160f3){#fig3}

###### Cumulative mortality and clinical features for the study base of 363 of incident colorectal cancer patients

                                              **Participating GP**                                                        
  ------------------------------------------- ---------------------- -------------------------------------- ------------- -------------
  *N*, patients (%)                           268 (73.8)             37 (10.2)                              58 (16.0)     363 (100)
  1-year mortality after discharge            66 (24.6)              13 (35.1)                              21 (36.2)     100 (27.5)
  3-year mortality after discharge            115 (42.9)             20 (54.1)                              27 (46.6)     162 (44.6)
                                                                                                                           
  *Tumour site*                                                                                                           
   Colon                                      183 (68.3)             30 (81.1)                              41 (70.7)     254 (70.0)
   Rectal                                     85 (31.7)              7 (18.9)                               17 (29.3)     109 (30.0)
                                                                                                                           
  *Age at discharge*                                                                                                      
   Median years (IQI)                         70 (62--80)            74 (67--80)                            72 (62--80)   72 (63--80)
   18--59 years                               56 (20.9)              5 (13.5)                               12 (22.4)     73 (20.1)
   60--74 years                               104 (38.8)             15 (40.5)                              21 (34.5)     140 (38.6)
   ⩾75 years                                  108 (40.3)             17 (45.9)                              25 (43.1)     150 (41.3)
                                                                                                                           
  *Gender*                                                                                                                
   Female                                     132 (49.3)             16 (43.2)                              29 (50.0)     177 (48.8)
   Male                                       136 (50.7)             21 (56.8)                              29 (50.0)     186 (51.2)
                                                                                                                           
  *Charlson Comorbidity Index at discharge*                                                                               
   Low (0)                                    139 (51.9)             17 (45.9)                              31 (53.4)     187 (51.5)
   Moderate (1--2)                            97 (36.2)              13 (35.1)                              18 (31.0)     128 (35.3)
   High (⩾3)                                  32 (11.9)              7 (18.9)                               9 (15.5)      48 (13.2)
                                                                                                                           
  *Previous cancer*                                                                                                       
   Yes                                        40 (14.9)              10 (27.0)                              13 (22.4)     63 (17.4)
   No                                         228 (85.1)             27 (73.0)                              45 (77.6)     300 (82.6)
                                                                                                                           
  *Tumour stage (TNM)*                                                                                                    
   I                                          25 (9.3)               2 (5.4)                                6 (10.3)      33 (9.1)
   II                                         94 (35.1)              10 (27.0)                              22 (37.9)     126 (34.7)
   III                                        71 (26.5)              11 (29.7)                              11 (19.0)     93 (25.6)
   IV                                         56 (20.9)              6 (16.2)                               13 (22.4)     75 (20.7)
   Unknown                                    22 (8.2)               8 (21.6)                               6 (10.3)      36 (9.9)
                                                                                                                           
  *Emergency admission*                                                                                                   
   Yes                                        65 (24.3)              21 (56.8)[a](#t1-fn2){ref-type="fn"}   17 (29.3)     103 (28.4)
   No                                         203 (75.7)             16 (43.2)                              41 (70.7)     260 (71.6)

Abbreviations: GP=general practitioner; IQI=interquartile interval; TNM=tumour, node, metastasis.

*P*⩽0.05 using a log-rank test for equality of survivor functions and a *χ*^2^ test for difference between groups comparing (1) patients with participating and nonparticipating GPs and (2) patients with involved and uninvolved participating GPs. No statistically significant differences were found between the former groups.

###### Characteristics of 268 incident colorectal cancer patients with GP involvement presenting with either: (a) alarm symptoms of cancer or symptoms related to any serious illness or with (b) vague or ill-defined symptoms not directly related to cancer or any other serious illness

                                                                                                  **(a) Alarm or any serious symptoms**   **(b) Vague symptoms**   **Total**
  ----------------------------------------------------------------------------------------------- --------------------------------------- ------------------------ -------------
  Median days (IQI)                                                                               37 (21--68)                             74 (40--152)             40 (23--71)
                                                                                                                                                                    
  *Age at first presentation of symptoms in primary care*                                                                                                          
   Median years (IQI)                                                                             71 (62--79)                             70 (62--81)              71 (62--80)
                                                                                                                                                                    
  *Age groups*                                                                                    n *(%)*                                 n *(%)*                  n *(%)*
   18--59 years                                                                                   41 (20)                                 15 (22)                  56 (21)
   60--74 years                                                                                   76 (38)                                 29 (43)                  105 (39)
   ⩾75 years                                                                                      84 (42)                                 23 (34)                  107 (40)
                                                                                                                                                                    
  *Sex*                                                                                                                                                            
   Female                                                                                         95 (47)                                 37 (55)                  132 (49)
   Male                                                                                           106 (53)                                30 (45)                  136 (51)
                                                                                                                                                                    
  *Comorbidity at first presentation of symptoms in primary care*[\*\*](#t2-fn3){ref-type="fn"}                                                                    
   Low (0)                                                                                        115 (57)                                52 (78)                  167 (62)
   Moderate (1--2)                                                                                67 (33)                                 12 (18)                  79 (29)
   High (⩾3)                                                                                      19 (9)                                  3 (4)                    22 (8)
                                                                                                                                                                    
  *Previous cancer*                                                                                                                                                
   Yes                                                                                            30 (15)                                 10 (15)                  40 (15)
   No                                                                                             171 (85)                                57 (85)                  228 (85)
                                                                                                                                                                    
  *Tumour stage (TNM)*                                                                                                                                             
   I                                                                                              20 (10)                                 5 (7)                    25 (9)
   II                                                                                             73 (36)                                 21 (31)                  94 (35)
   III                                                                                            54 (27)                                 17 (25)                  71 (26)
   IV                                                                                             37 (18)                                 19 (28)                  56 (21)
   Unknown                                                                                        17 (8)                                  5 (7)                    22 (8)
                                                                                                                                                                    
  *Emergency admission*                                                                                                                                            
   Yes                                                                                            43 (21)                                 22 (33)                  65 (24)
   No                                                                                             158 (79)                                45 (67)                  203 (76)
                                                                                                                                                                    
  *Patient presented with change in bowel habits*                                                                                                                  
   Yes                                                                                            101 (50)                                25 (37)                  126 (47)
   No                                                                                             101 (50)                                42 (63)                  143 (53)
                                                                                                                                                                    
  *Patient presented with blood in stools*[\*\*](#t2-fn3){ref-type="fn"}                                                                                           
   Yes                                                                                            94 (47)                                 7 (10)                   101 (38)
   No                                                                                             107 (53)                                60 (90)                  167 (62)

Abbreviations: GP=general practitioner; IQI=interquartile interval; TNM=tumour, node, metastasis.

^\*^*P*⩽0.05 using independent sample *t*-test for difference in median diagnostic intervals (log transformed distributions) comparing alarm or any serious with vague.

*P*⩽0.05 using *χ*^2^ test for difference between groups (alarm or any serious *vs* vague symptoms).

###### Cumulative mortality (MR) and adjusted 3-year mortality ORs for 268 incident colorectal cancer patients with GP involvement, according to the length of the diagnostic interval (time from first presentation of symptoms in primary care to diagnosis).

  ------------------------------------------------------------------------ --------- -------- ---------------------------- ---------------------------------------------------------
  **Diagnostic interval**                                                   ***N***   **MR**  **Crude OR** (**95% CI)**    **Adjusted[a](#t3-fn2){ref-type="fn"} OR** (**95% CI)**
  *3-year mortality after diagnosis*                                                                                       
  *(a) Patients presenting with alarm or any serious symptoms (*N*=201)*                                                   
   0--4 weeks                                                                 75       48%    2.15 (1.14--4.08)            2.56 (1.29--5.05)
   5--11 weeks                                                                90       30%    1 (ref.)                     1 (ref.)
   ⩾12 weeks                                                                  36       47%    2.09 (0.94--4.62)            2.04 (0.87--4.77)
                                                                                                                            
  *(b) Patients presenting with vague symptoms (*N*=67)*                                                                   
   0--4 weeks                                                                 10       10%    *Comparison not justified*   *Comparison not justified*
   5--11 weeks                                                                27       56%    1 (ref.)                     1 (ref.)
   ⩾12 weeks                                                                  30       57%    0.96 (0.37--2.98)            0.71 (0.32--2.91)
                                                                                                                            
  *1-year mortality after diagnosis*                                                                                       
  *(a) Patients presenting with alarm or any serious symptoms (*N*=201)*                                                   
   0--4 weeks                                                                 75       25%    1.70 (0.79--3.63)            2.09 (0.92--4.73)
   5--11 weeks                                                                90       17%    1 (ref.)                     1 (ref.)
   ⩾12 weeks                                                                  36       31%    2.20 (0.89--5.41)            2.35 (0.88--6.26)
                                                                                                                            
  *(b) Patients presenting with vague symptoms (*N*=67)*                                                                   
   0--4 weeks                                                                 10       10%    *Comparison not justified*   *Comparison not justified*
   5--11 weeks                                                                27       37%    1 (ref.)                     1 (ref.)
   ⩾12 weeks                                                                  30       23%    0.52 (0.16--1.64)            0.40 (0.11--1.48)
  ------------------------------------------------------------------------ --------- -------- ---------------------------- ---------------------------------------------------------

Abbreviations: GP=general practitioner; OR=odds ratio; CI, confidence interval.

Adjusted for tumour site (colon/rectal), Charlson Comorbidity Index (0/1--2/⩾3), age (18--59/60--74/⩾75), and sex. To address the possibility that emergency admission was a confounder and not an intermediate step in the diagnostic pathway, we additionally adjusted for emergency admission and repeated the analyses after excluding patients with emergency admissions. In both subanalyses, we saw comparable trends and no changes in estimates (data not shown).
